On June 5 the Ministry of Health of the Russian Federation registered Biocad's Ilsira
(levilimab) as a treatment for severe COVID-19. Ilsira is one of several monoclonal …

Acting on the cytokine cascade is key to preventing disease progression and death in
hospitalised patients with COVID-19. Among anti-cytokine therapies, interleukin (IL)-6 …

The COVID‐19 pandemic, induced by severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2), has caused great impact on the global economy and people's daily life. In …

After three years and a half since the pandemic due to the Severe Acute Respiratory
Syndrome coronavirus 2 (SARS-CoV-2) causing Coronavirus Disease 2019 (COVID-19) …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can induce mild
to life-threatening symptoms. Especially individuals over 60 years of age or with underlying …

As of April 4, 2020, coronavirus disease-2019 (COVID-19) has been confirmed in 1,395,136
people worldwide, with a mortality of approximately 5.8%. Since the COVID-19 outbreak …

Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has seen multiple anti-SARS-CoV-2 …

The outbreak of COVID-19, the disease caused by infection of the coronavirus SARS-CoV-2
that began in December 2019 in Wuhan, China, has caused more than 2 990 559 confirmed …

The response to the COVID-19 pandemic has shown that exceptional efforts can
dramatically accelerate the clinical development of vaccines. We propose that it is time to …

Antibody cocktails represent a promising approach to prevent SARS-CoV-2 escape. The
determinants for selecting antibody combinations and the mechanism that antibody cocktails …